Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Autor: Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B Kristensen, Mahesh K B Parmar, Tom Ehlen, Gordon C Jayson, Nick Johnson, Ann Marie Swart, René Verheijen, W Glenn McCluggage, Tim Perren, Pierluigi Benedetti Panici, Gemma Kenter, Antonio Casado, Cesar Mendiola, Gavin Stuart, Nick S Reed, Sean Kehoe, Claes Tropé G., Stephen Dobbs, Sharadah Essapen, P. Hoskins, John Green, E. Gilby, M. Van Baal, Jeremy Twigg, Maria E.L. Van Der Burg, Keith Godfrey, Angel J. Lacave, R. Angioli, Rahul Nath, Kirk Chin, Charles Redman, R. Lotocki, Adeola Olaitan, B. Mosgaard, G. Rustin, Thomas Ind, Mojca Persic, Martin Hogg, J. Van Der Velden, J. Ledermann, Peter Sykes Peter Sykes, Krishnawam Madhavan, P. Kannisto, Vicky Hird, A. Evans, R. Sandvei R., P. Gauthier, D.J. Cruickshank, P.B. Ottevanger, Sheila Pearson, Henry Kitchener, Marcia Hall, P. Bessette, S. Pecorelli, E. Gerdin, Tito Lopes, Andrew Fish, Clare Barlow., K. Van Eygen, A. Floquet, B. Tholander, N. Gul, Robert Gornall, David Luesley, Philip Kirwan, Paul Symonds, Richard Henry, David Poole, Ian McNeish, Mark Hocking, Al Sammaraie, P. Speiser, E. Leblanc, J.A. Green, C.F. De Oliveira, R. Grimshaw, P. Zola, David Parkin, Martin Lamb, Anne Hong, Alan Gillespie, Abdel Hamid, Ahmed Ahmed, M. Plante, B. De Valk, A. Nordin, Andrew Clamp, David Perez, Graham Dark Graham Dark, Michelle Ferguson, Carol MacGregor, Geraldine Skailes, Rachel Jones, G. Cawdell, Simon Leeson, L. Elit, C. Dittrich, W. Gotlieb, John Cullimore, Barbara Crosse, Paul Ridley, Anthony Head, Joaquin Nieto, Saif Awwad, Dirk Brinkmann, Damian Eustace, Andrew Hindley, D. Katsaros, C. Popadiuk, Tome Kristeller, C. Redman, S. Chan, C. Marth, Dennis Yiannakis, Kate Lankaster, Gareth Beynon, Anwar Suhail, Fernando Indrajit, Mary Quigley, Olu Adeyemi, Fiona Lofts, Orla McNally, Amanda Tristam, Martin Lee, R. Counsell, N. Gleeson, A. Papadopoulos, T. Maggino, A. Honkoop, P. Ghatage, J.B. Vermorken, J. De Greve, K. Boman, E Petru, F. Amant

Publikováno v: Lancet Oncology, 19, 12, pp. 1680-1687
Obstetrical and Gynecological Survey, 74(3), 156-158. Lippincott Williams and Wilkins
MRC CHORUS study investigators 2018, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials ', The Lancet Oncology, vol. 19, no. 12, pp. 1680-1687 . https://doi.org/10.1016/S1470-2045(18)30566-7
Vergote, I, Coens, C, Nankivell, M, Kristensen, G B, Parmar, M K B, Ehlen, T, Jayson, G C, Johnson, N, Swart, A M, Verheijen, R, McCluggage, W G, Perren, T, Panici, P B, Kenter, G, Casado, A, Mendiola, C, Stuart, G, Reed, N S & Kehoe, S 2019, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: Pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials ', Obstetrical and Gynecological Survey, vol. 74, no. 3, pp. 156-158 . https://doi.org/10.1097/01.ogx.0000554460.78765.59
Jayson, G 2018, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. ', Lancet Oncology, vol. 19, no. 12, pp. 1680-1687 . https://doi.org/10.1016/S1470-2045(18)30566-7
Lancet Oncology, 19, 1680-1687
The Lancet Oncology, 19(12), 1680-1687. Lancet Publishing Group

Summary Background Individual patient data from two randomised trials comparing neoadjuvant chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to examine long-term outcomes for patients and to identify any prefe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f32bf7e089ed9921db1ad91c3ad4e088
https://hdl.handle.net/2066/200265

Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer: A Phase Ib Study

Autor: Joaquin Fra, Miguel F. Sanmamed, J.P. Berros, Noemi Villanueva, Marta I. Sierra, M. Luque, Raquel Losa, Angel J. Lacave, Paula Jiménez Fonseca, Guillermo Crespo, Yolanda Fernández, Emilio Esteban, C. Muriel, Pilar Blay

Publikováno v: International Journal of Gynecologic Cancer. 21:478-485

IntroductionPegylated liposomal doxorubicin (PLD) is currently the reference treatment for platinum-resistant ovarian cancer. The combination of PLD and gemcitabine and the administration of gemcitabine at a fixed dose rate infusion (FDRI) seem to ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::529fb9f564a77bdc8cab481d5c0084e4
https://doi.org/10.1097/igc.0b013e31820d738c

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

Autor: Luis de Sande González, José Luis García-López, Humberto Bovio, Ignacio Peláez, Manuel Valladares, Jesús García-Foncillas, Margarita Reboredo, Carlos García-Girón, Jose María Vieitez, Angel J. Lacave

Publikováno v: Investigational New Drugs. 29:1038-1044

Purpose To determine the efficacy of the addition of gefitinib to raltitrexed in patients with colorectal cancer (CRC) that have progressed after first line chemotherapy. The study also sought to explore the safety of the combination and to investiga

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a954ed2a4d411e1f44a380242043b9e1
https://doi.org/10.1007/s10637-010-9400-z

Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): Results of a prospective randomized study

Autor: Marta Capellan, M. Luque, Noemi Villanueva, I. Muñiz, Jose-Luis de Sande, Angel J. Lacave, J. Buesa, Beatriz Mareque, Emilio Esteban, Yolanda Fernández, José-Luis Fernandez, Norberto Corral, Jose María Vieitez, Paula Jimenez, Joaquin Fra, E. Estrada

Publikováno v: Lung Cancer. 55:173-180

To evaluate possible improvement in objective response of adding vinorelbine (V) to the combination of cisplatin/gemcitabine (CG) in induction chemotherapy for stage III NSCLC, patients (n=154) agedor =75 years, Karnofsky indexor =70%, were stratifie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf8e783ee73c7f1133e3e5405599daa7
https://doi.org/10.1016/j.lungcan.2006.09.021

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination

Autor: Emilio Esteban-Gonzalez, Esther Uña, I. Palacio, Jose María Vieitez, Angel J. Lacave, Noemi Villanueva, Joaquin Fra, Yolanda Fernández, Beatriz Mareque, I. Muñiz

Publikováno v: Investigational New Drugs. 23:597-601

To assess the efficacy of carboplatin when used as a single agent in patients with advanced non small cell lung cancer (NSCLC) and who are refractory to chemotherapy with a non-platinum combination, we recruited patients (n=40) NSCLC patients, 36 of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce44dcd7de750b3214b7e531346c469b
https://doi.org/10.1007/s10637-005-0556-x